Close Menu


The firm said that its instrument business was negatively impacted by lower consumables revenues, product mix, and currency translation.

During the quarter, the firm launched two new Familion genetic tests while preparing for the potential launch of its first drug.

PGxHealth has charged Toronto Research Chemicals and Santa Cruz Biotechnology for infringement because they both market the compound apadenoson, the primary ingredient of Stedivaze, a coronary vasodilator that PGxHealth is developing for myocardial perfusion imaging.

Bio-Rad, Sungkyunkwan University, Transgenomic, and Symphogen awarded US patents.

For the second month in a row, the GWDN Index and the broader market dropped sharply. Only nine firms in the Index saw their stock price gain ground in June.

The firm will use the proceeds to develop and commercialize its lead drug for depression, fund clinical trials for it coronary vasodilator, and other things.

Despite increased spending, its full-year net loss dropped sharply due to last year's charge of $55.1 million for purchased in-process R&D.

Pairings: Jun 9, 2010


Debra Schneider

The firm's full-year revenues were up 26 percent, according to the preliminary results. It also expects to offer all remaining shares of common stock on its existing shelf registration statement.

The firm's instrument revenues grew 12 percent year over year, and it launched its KRAS test kit in Europe.


The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.